I-MAB
General Information | |
Business: |
We are a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. We were founded to capture the opportunities presented by the confluence of two major developments––the emergence of an attractive and growing biologics market in China, and the revolutionary scientific breakthroughs in cancer and autoimmune disease medicines. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 185 |
Founded: | 2007 |
Contact Information | |
Address | Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, People’s Republic of China |
Phone Number | +86 21-6057-8000 |
Web Address | http://www.i-mabbiopharma.com/en/ |
View Prospectus: | I-MAB |
Financial Information | |
Market Cap | $778.3mil |
Revenues | $6.7 mil (last 12 months) |
Net Income | $-146.8 mil (last 12 months) |
IPO Profile | |
Symbol | IMAB |
Exchange | NASDAQ |
Shares (millions): | 7.4 |
Price range | $14.00 - $14.00 |
Est. $ Volume | $103.7 mil |
Manager / Joint Managers | Jefferies/ CICC |
CO-Managers | China Renaissance/ Huatai Securities |
Expected To Trade: | 1/17/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |